❌

Normal view

There are new articles available, click to refresh the page.
Before yesterdayMain stream

FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss

By: Beth Mole
10 November 2026 at 14:43

The Food and Drug Administration is warning that popular obesity drugsβ€”including Ozempic, Wegovy, Zepbound, and Mounjaroβ€”may carry a "potential increased risk" of a rare eye condition that can lead to permanent vision loss.

In a drug safety communication Monday, the FDA said it will now require makers of GLP-1 receptor agonist drugs to add a warning about that risk on their drug labels. The specific eye condition it warns of is called non-arteritic anterior ischemic optic neuropathy or NAION. The condition is caused by restricted blood flow to the optic nerve, which leads to swelling and cell death and ultimately damages the nerve, causing abrupt vision loss that can often be permanent.

It's unknown how GLP-1 drugs may cause NAION. The condition is rare overall, occurring in somewhere between two and 10 people in 100,000 in the general population, according to the American Academy of Ophthalmology. These small numbers have made it more difficult to determine with certainty if there is a connection. Further complicating the potential link is the fact that the risk factors for developing NAION are common among patients taking GLP-1 drugs. The risk factors include diabetes, cardiovascular disease, high blood pressure, high cholesterol, metabolic syndrome, and obstructive sleep apnea.

Read full article

Comments

Β© Getty | George Pachantouris

The FDA wants to pull its approval of a drug. It’s not so easy.

In May 2021, the US Food and Drug Administration released a lengthy briefing document on an experimental medication for a rare autoimmune form of vasculitis that often damages the kidneys and lungs. The agency was on the fence about whether to approve the treatment, and it wanted an independent advisory committee to weigh in. Among the questions at hand: Was the drug meaningfully better than existing therapies?

Participants in the study, which had been conducted by the California biotechnology company ChemoCentryx, did appear to have slightly higher rates of symptom remission after one year. But according to the FDA, it was hard to interpret the results because the study’s design had been less than optimal. Some advisory committee members expressed a similar view. The effect of the drug, said one, β€œis just not well verified by this study.”

At the same time, many patients, and some physicians, saw in the data a potentially helpful medication, one that might lessen patients’ reliance on steroids, which are highly effective but often cause severe side effects.

Read full article

Comments

Β© Artem Stepanov via Getty Images

Peptide peddlers cheer as RFK Jr. unilaterally grants access, overruling FDA

By: Beth Mole
28 October 2026 at 22:17

Anti-vaccine Health Secretary Robert F. Kennedy has unilaterally passed a rule that will allow specialty pharmacies to sell six specific peptide drugs, overruling scientists at the Food and Drug Administration.

The peptides are popular among members of Kennedy's Make America Health Again movement, and many prominent MAHA figures and Kennedy allies sell them. Kennedy said he uses some of the peptides and called himself a "big fan." But FDA scientists continue to say there is insufficient evidence to show if they're effective, and they are potentially dangerous. In 2023, the safety concerns led the FDA to remove the six peptides from a list of drugs that can be made by specialty pharmacies called compounding pharmaciesβ€”which make customized formulations of drugs for patients, or, in cases such as this, specialty drugs in bulk.

Kennedy's new rule sidesteps the need to formally undo that FDA action. The rule is titled "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" and was made available Wednesday on the Federal Register, with the final publication date set for October 30. The rule does not change the regulatory status of the peptide; instead, it states the Department of Health and Human Services (HHS) will no longer take enforcement action against compounding pharmacies for making the peptides, essentially giving them a green light to freely produce and sell them. Kennedy had quietly proposed this rule earlier this month.

Read full article

Comments

Β© Kevin Dietsch / Staff | Getty Images News

RFK Jr. proposes FDA look the other way on unproven peptides, report says

By: Beth Mole
16 October 2026 at 17:05

Under Health Secretary Robert F. Kennedy Jr., the Food and Drug Administration is moving forward with plans to ease access to unproven peptide drugs that are popular among members of Kennedy's Make America Healthy Again movementβ€”despite FDA staff scientists finding that the drugs have not been sufficiently studied to establish safety and efficacy and may cause harms.

The FDA submitted an "Interim Access Policy" on peptides for review by the White House, according to a filing notice posted on an Office of Management and Budget website. The posting does not provide information on the proposed policy. But people familiar with the proposal told The Associated Press that it would give the FDA "enforcement discretion" on certain peptide drugs. This would allow the agency to choose not to enforce current restrictions on peptides and provide an assurance to specialty pharmacies eager to start making them that they will not be targeted by the agency.

The Department of Health and Human Services, which oversees the FDA, did not respond to a request for comment from Ars Technica.

Read full article

Comments

Β© Getty | Leandro Lozada

❌
❌